| Sumario: | Background: Omega-3 fatty acid (n-3FA) supplementation may improve total hydroxyvitamin D (25OHD) levels in people with normal or low vitamin D levels. However, there was no agreement on the potential therapeutic benefit of n-3FA on vitamin D toxicity. Objective: The current randomized controlled clinical study (RCT) sought to determine if daily omega-3 fatty acid (n-3FA) supple-mentation affected 25-hydroxyvitamin D (25OHD) levels. Methods: One hundred and twenty Jordanians aged 22 to 55 were randomly allocated into three groups supplemented with the dose of 50,000 IU VD3 taken weekly (D3) alone, 300 mg n-3FA taken daily (n-3FA) alone, or their com-bination (50,000 IU VD3 taken weekly + 300 mg n-3FA taken daily (D+). In addition, fasting baseline and follow-up (ten weeks; eight weeks supplementation plus two weeks washout) of serum 25 hydroxyvitamin D (25OHD), parathyroid hormone (PTH), calcium, and leptin were assayed. Results: The n-3FA supplementation significantly decreased mean serum 25OHD levels (11.97±4.6 vs 16.5±4.8, P<0.001) compared with their peers in the D3 group who showed a significant increase in 25OHD levels (41.15±11.7 vs 19.34±6.8, P<0.001). The follow-up PTH mean levels were pro-portionally accompanied by significant alterations of 25OHD levels in the two study groups. Conclusions: This novel RCT provides that eight weeks of n-3FA therapy significantly reduced 25OHD levels, which adverse effects may accompany vitamin D status and its health-related consequences, such as bone homeostasis, cardiovascular disease, and COVID-19 conditions.
|
|---|